Endpoints News

Roivant gets an FDA approval		Read in browser

Thank you for reading, dupa dupackia!

basic

UPGRADE

M T W Th Fri

28 August, 2026

One night, one room: the founders, scientists and investors behind the Endpoints 11, together in Boston this September. Reserve your spot now and save with the early bird rate.

news

Future of AstraZeneca’s gene silencer in heart disease uncertain after trial failure

Roivant’s road to a potential blockbuster begins with Lisraya FDA approval

Gilead gets another HIV treatment approval, extending lenacapavir's dominance

Peer Review

Daiichi Sankyo to give commercial team a makeover; Novo Nordisk's GPCR partner finds CMO

Lilly's move to hide Phase 1 pipeline draws mixed reviews

Sep 03

11:00 am ET

How leading pharma organizations are putting AI agents to work

in case you missed it

Q&A: Akeso CEO spells out why she thinks its biliary tract cancer data are a big deal

Pharma's legal battle over Medicare negotiations reaches 'dead end'

A couple months in, impacts of US government's GLP-1 pilot program take shape

News Briefing

Moderna's $2B offering; AstraZeneca-Amgen and Biokin chalk up Phase 3 wins

Generate:Biomedicines discloses early respiratory drug data after congress poster leak

EU flags shortage of schizophrenia drug injections due to manufacturing issues

Big Pharma steps up fight against counterfeit weight-loss drugs

Elizabeth Cairns is in hot and sunny Munich for this year’s ESC Congress. Keep checking our homepage throughout today and over the weekend to stay updated.

Reynald Castaneda

Deputy Editor, Endpoints News